Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | Anthracycline + Cyclophosphamide + Nivolumab + Paclitaxel |
| Indication/Tumor Type | estrogen-receptor positive breast cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | estrogen-receptor positive breast cancer | predicted - sensitive | Anthracycline + Cyclophosphamide + Nivolumab + Paclitaxel | Phase III | Actionable | In a Phase III trial (CheckMate 7FL), the addition of Opdivo (nivolumab) to neoadjuvant chemotherapy with Taxol (paclitaxel) for 12 weeks followed by Opdivo (nivolumab) plus Cytoxan (cyclophosphamide) and Anthracycline resulted in improved pathologic complete response rate (44.3% vs 20.2%) compared to placebo plus neoadjuvant chemotherapy in patients with high-risk, early stage, ER (ESR1)-positive, CD274 (PD-L1)-positive (CPS>=1%), ERBB2 (HER2)-negative breast cancer (PMID: 39838118; NCT04109066). | 39838118 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (39838118) | Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial. | Full reference... |